Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv Cohort

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Stoll, Matthias ^a   Kollan, Christian ^b   Bergmann, Frank ^c   Bogner, Johannes ^d   Faetkenheuer, Gerd ^e   Fritzsche, Carlos ^f   Hoeper, Kirsten ^a   Horst, Heinz August ^g   van Lunzen, Jan ^h   Plettenberg, Andreas ⁱ   Reuter, Stefan ^j   Rockstroh, Jürgen ^k   Stellbrink, Hans Jürgen ^l   Hamouda, Osamah ^b   Bartmeyer, Barbara ^b  

^a Medical University   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^f ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ Ifi Institute for Interdisciplinary Medicine   (Germany)

^j UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^k UNIVERSITY HOSPITAL BONN   (Germany)

^l Infektionsmedizinisches Centrum Hamburg   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; GENERIC DRUG; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE;

ARTICLE; CALCULATION; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; DISEASE COURSE; DRUG COST; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; TAX; TREATMENT DURATION; ADULT; DRUG ANTAGONISM; DRUG COMBINATION; ECONOMICS; PRESCRIPTION; STATISTICS;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; COST SAVINGS; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; FEMALE; FOLLOW-UP STUDIES; GERMANY; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HUMANS; MALE; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 80052567237     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023946     Document Type: Article

References (30)

1. Palella F, Delaney K, Moorman A, Loveless M, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 338: 853.
2. Walensky R, Paltiel A, Losina E, Mercincavage L, Schackman B, et al. (2006) The survival benefits of AIDS treatment in the United States. The Journal of infectious diseases 194: 11-19.
3. Hogg R, Lima V, Sterne J, Grabar S, Battegay M, et al. (2008) Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293-299.
4. DAIG (2010) German-Austrian Treatment Guidelines for antiretroviral therapy (Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion, Stand 4, März 2010). http://www.rki.de/cln_169/nn_753398/DE/Content/InfAZ/H/HIVAIDS/Therapie/Leitlinien/D__A__antiretroviral__03__10,templateId=raw,property=publicationFile.pdf/D_A_antiretroviral_03_10.pdf, accessed 21.Aug.2011.
5. DHHS (2011) Guidelines for the Use of Antiretroviral Agents in HIV-1 infected Adults and Adolescents. http://www.rki.de/cln_169/nn_753398/DE/Content/InfAZ/H/HIVAIDS/Therapie/Leitlinien/D__A__antiretroviral__03__10,templateId=raw,property=publicationFile.pdf/D_A_antiretroviral_03_10.pdf, accessed 21.Aug.2011.
6. EACS (2009) Guidelines Clinical Management and Treatment of HIV-infected Adults in Europe, Version 5.4. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/1_treatment_of_hiv_infected_adults.pdf, accessed 21.Aug2011.
7. Kingham R, Wheeler J, (2009) Government Regulation of Pricing and Reimbursement of Prescription Medicines: Results of a Recent Multi-Country Review. Food Drug LJ 64: 101-225.
8. Waning B, Kaplan W, King A, Lawrence D, Leufkens H, et al. (2009) Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bulletin of the World Health Organization 87: 520-528.
9. Stoll M, Claes C, Schulte E, Graf S, Schmidt R, (2002) Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. European journal of medical research 7: 463.
10. German Federal Ministry of Justice: German Social Insurance Code from 1989, last revision from 28th July 2011.
11. Levy A, James D, Johnston K, Hogg R, Harrigan P, et al. (2006) The direct costs of HIV/AIDS care. The Lancet infectious diseases 6: 171-177.
12. Bätzing Feigenbaum J, Kollan C, Kühne A, Matysiak Klose D, Gunsenheimer Bartmeyer B, et al. (2010) Cohort profile: the German ClinSurv HIV project-a multicentre open clinical cohort study supplementing national HIV surveillance. HIV medicine.
13. Stargardt T, Schreyögg J, Busse R, (2007) Pricing behaviour of pharmacies after market deregulation for OTC drugs: The case of Germany. Health Policy 84: 30-38.
14. Augurzky B, Göhlmann S, Greß S, Wasem J, (2009) Effects of the German reference drug program on ex factory prices of prescription drugs: a panel data approach. Health Economics 18: 421-436.
15. Davidson I, Beardsell H, Smith B, Mandalia S, Bower M, et al. (2010) The frequency and reasons for antiretroviral switching with specific antiretroviral associations: The SWITCH study. Antiviral research 86: 227-229.
16. McKinnon J, Mellors J, Swindells S, (2009) Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antiviral therapy 14: 1.
17. Metzner K, Rauch P, von Wyl V, Leemann C, Grube C, et al. (2010) Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. The Journal of infectious diseases 201: 1063-1071.
18. Tomeczkowski JG-HS, Biteeva I, Kruppert S, Stoll M, (2010) Estimation of patients with antiretroviral therapy potentially used for HIV prevention(postexposure prophylaxis, mother to child transmission prophylaxis) in Germany. ISPOR. Prague, Czech Republic.
19. Shimatani T, Hirokawa S, Tawara Y, Hamai K, Matsumoto M, et al. (2009) Comparing the Acid-Suppressive Effects of Three Brands of Generic Lansoprazole with the Original: Pharmacokinetic Bioequivalence Tests Do Not Necessarily Guarantee Pharmacodynamic Equivalence. Digestive diseases and sciences 54: 2385-2390.
20. Hellström J, Rudholm N, (2004) Side effects of generic competition? The European Journal of Health Economics 5: 203-208.
21. Ledergerber B, Battegey M, Bernasconi M, Vernazza P, Hirschel B, et al. (2011) Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV medicine 12: 279-288.
22. Green C, Maclure M, Fortin P, Ramsay C, Aaserud M, et al. (2010) Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane database of systematic reviews (Online) pp. CD008654.
23. Rizzo J, Zeckhauser R, (2009) Generic script share and the price of brand-name drugs: the role of consumer choice. International journal of health care finance and economics 9: 291-316.
24. Borroto-Esoda K, Parkin N, Miller M, (2007) Short communication A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine. Antiviral chemistry & chemotherapy 18: 297-300.
25. Chowers M, Gottesman B, Leibovici L, Schapiro J, Paul M, (2010) Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis. European Journal of Clinical Microbiology & Infectious Diseases 29: 779-786.
26. Borroto-Esoda K, Vela J, Myrick F, Ray A, Miller M, (2006) In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antiviral therapy 11: 377.
27. Bartmeyer B, Stoll M, Bogner J, Fätkenheuer G, Stellbrink HJ, et al. (2010) Estimation of persons infected with HIV under antiretroviral therapy in Germany (2006-2008). Int AIDS Congress 2010. Vienna, Austria: CDC0504.
28. Mannheimer S, Matts J, Telzak E, Chesney M, Child C, et al. (2005) Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS care 17: 10-22.
29. Roebuck M, Liberman J, (2009) Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data. Health Services Research 44: 988-1009.
30. von der Schulenburg JM, (2005) German health care system in transition. The difficult way to balance cost containment and solidarity. Eur J Health Econ 6: 183-187.